Biostrain - development of a novel medical device for measuring and stabilising core-muscle imbalances, from lumbar-patients to elite-athletes.
Lead Participant:
PERFORMANCE BIOMECHANICS LIMITED
Abstract
**Public description**
Our experienced and proven team is developing Biostrain, a novel medical device to enable clinicians and users to diagnose and treat imbalances in muscle groups known to cause lower-back pain, spinal and hamstring injuries.
This groundbreaking new technology will offer major advantages over current techniques, from a wide variety of users from stroke patients to back pain sufferers, to orthopaedic specialists and amateur & elite sports-people. The market-pull for this solution have been proven through rigorous customer discovery.
The device is simple to use, and will be developed, manufactured & distributed within the UK in collaboration with proven medical device development partner Lucid Group.
Biostrain addresses wider economic and social challenges including UK Industrial Strategy and NHS long-term priorities for preventive healthcare, focus on helping people keep active, reducing susceptibility to debilitating injury. Lower-back-pain increased 12% 1990-2010, particularly in 40-60 year-olds. Resultant production-loss cost were £10,7Bn/year with NHS costs exceeding £2Bn. The project is particularly timely with regard to the Covid pandemic, and the increase in home-working, which is expected to produce an increase in lower back complaints in the coming years, due to poor posture.
Lightweight and portability allows for patient home use whilst clinicians can monitor progression via cloud upload.
In sports, users will be offered a genuine advantage over any other method of hamstring exercise or monitoring. This will enable sportspeople and clinicians to significantly reduce the risk of hamstring injury, improve recovery for existing injuries, and improve performance & speed in healthy athletes.
Our experienced and proven team is developing Biostrain, a novel medical device to enable clinicians and users to diagnose and treat imbalances in muscle groups known to cause lower-back pain, spinal and hamstring injuries.
This groundbreaking new technology will offer major advantages over current techniques, from a wide variety of users from stroke patients to back pain sufferers, to orthopaedic specialists and amateur & elite sports-people. The market-pull for this solution have been proven through rigorous customer discovery.
The device is simple to use, and will be developed, manufactured & distributed within the UK in collaboration with proven medical device development partner Lucid Group.
Biostrain addresses wider economic and social challenges including UK Industrial Strategy and NHS long-term priorities for preventive healthcare, focus on helping people keep active, reducing susceptibility to debilitating injury. Lower-back-pain increased 12% 1990-2010, particularly in 40-60 year-olds. Resultant production-loss cost were £10,7Bn/year with NHS costs exceeding £2Bn. The project is particularly timely with regard to the Covid pandemic, and the increase in home-working, which is expected to produce an increase in lower back complaints in the coming years, due to poor posture.
Lightweight and portability allows for patient home use whilst clinicians can monitor progression via cloud upload.
In sports, users will be offered a genuine advantage over any other method of hamstring exercise or monitoring. This will enable sportspeople and clinicians to significantly reduce the risk of hamstring injury, improve recovery for existing injuries, and improve performance & speed in healthy athletes.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| PERFORMANCE BIOMECHANICS LIMITED | £220,780 | £ 154,546 |
Participant |
||
| LUCID GROUP LIMITED | £572,330 | £ 400,631 |
People |
ORCID iD |
| Neil Day (Project Manager) |